ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / PBH / forecast
BHVN (44) RCUS (19) PHVS (59) HCM (34) ⌘ Pro Terminal →

Prestige Consumer Healthcare Inc. (PBH) 12-Month Stock Forecast & Price Target Cone

$49.73 +1.37% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $49.76

Prestige Consumer Healthcare Inc. (PBH) carries a Roarable Rating of C (Hold) with 62/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C • HOLD / WATCH Cap $2.32B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on PBH Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is PBH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Prestige Consumer Healthcare Inc. (NYSE: PBH) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $49.73 (+1.37% 1D, market cap $2.32B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, PBH ranks #149 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does PBH compare to BHVN and RCUS in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBH carries a Roarable C (62/100 RQD), trailing P/E of 12.1x, gross margin of 54.7%, and ROIC of 13.8%. By comparison, BHVN (Biohaven Ltd.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $2.33B) and RCUS (Arcus Biosciences Inc.) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $2.32B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for PBH?
▼

Per PBH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001295947), Prestige Consumer Healthcare Inc. generated $1.09B in revenue (-4.3% YoY), $190.3M in net income, and $246.4M in free cash flow against $3.49B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $49.76 (+0.06%)🧬 Cannibal Buyback (-2.64% YoY Shares)⚙️ Cash Engine: 14/20 (B-) • 22.6% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 62/100 (C) historically posted market-perform odds over rolling 90-day windows (+0.7% avg 90D alpha vs SPY • 54.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C
025507510062
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C+ · Rk D+
Cash (14)Whales (9)SEC (11)Macro (11)CEO (17)
Each axis scored 0–20
12M PRICE TARGET CONE+1.8% Base Target
$75 Bull$51 Base$39 Bear
📬 FREE PBH RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for PBH)Realized 20D OHLCV Swing Band: ±6%
Deterministic 5-Pillar Attribution (62/100 Composite)
🔍 WHY PBH SCORES 62/100 (C) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Insider Conviction & Share Dilution+17/20 pts (27% of score)

SEC Form 4 / 13F Thermometer: 85% Net Buy • Cannibal Buyback (-2.64% YoY Shares)

▲ #2 Bullish Driver: Cash Engine Quality+14/20 pts (23% of score)

SEC XBRL FY 2025 (10-K): 22.6% FCF Margin ($246.4M FCF) & 54.7% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning9/20 pts (-11 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-11 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
54
Grade C-$48.50+1.8% Next Q
Q2 (-2Q)
57
Grade C$49.36-4% Next Q
Q3 (-1Q)
59
Grade C$47.39+4.9% Next Q
Current
62
Grade C$49.73+0.7% Hist 90D α
Trajectory: C- (54) → C (62)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the PBH Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 62/100 (C) score, PBH faces multiple-compression risk if 12.1x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-2.64% YoY Shares) — any gross margin slip below 52.2% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($48.42) or 200D SMA ($53.92) invalidates the momentum regime and cuts Target Base ($50.63) toward Bear Floor ($39.49).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $PBH• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “PBH Beats Next Quarter EPS Consensus (Dec 29, 2026) & Holds Above 200D SMA”
YES 62%NO 38%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your PBH Position Size: $10,000

Shares at $49.73: 201.1 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $39.49
$7,941
$-2,059 (-20.6%)
12M Consensus BaseTarget $50.63
$10,181
+$181 (+1.8%)
12M Bull Case BreakoutTarget $74.62
$15,005
+$5,005 (+50.1%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (28 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 2
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$5374%A
Goldman SachsSector Coverage LeadBUY$7069%B
JP MorganUS Large-Cap ResearchHOLD$4558%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (PBH Tape Review)

  • ✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
  • ✓Forensic Red-Light accounting & dilution traps to review on your watchlist
  • ✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
PBH // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -10.09%▲ RESISTANCE BREAKOUT
2026-11-03O $48.75H $49.73L $48.75C $49.73VOL 371.5K
RES: $49.49SUP: $44.62SMA50: $48.42SMA200: $53.92
$64.98$58.92$52.86$46.80$40.74RES $49.49SUP $44.62$49.732026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

PBH Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 PBH Butterfly Map → + Track PBH →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
2.7%/yr Implied 5Y Growth

vs. -4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on PBH today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for PBH. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for PBH today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (PBH)

Health Care Rank #149 of 1016 ⚔️ BHVN vs PBH Full Matrix →

1. Head-to-Head Health Care Peer Comparison (PBH vs. BHVN, RCUS, PHVS, HCM)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Prestige Consumer Healthcare Inc. (PBH) ranks #149 by composite RQD confidence (62/100, grade C) and #231 by equity capitalization ($2.32B). Within this direct 5-issuer industry benchmark cohort, HCM leads on earnings valuation at 5.2x trailing P/E, while PBH leads on capital efficiency and profitability with 13.8% ROIC and 54.7% gross margin. PBH currently leads its immediate peer cohort in composite quantitative strength at 62/100 (C).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
PBH ACTIVE
Prestige Consumer Healthcare Inc.
C 62/100 12.1x 54.7% 13.8% +1.37% $2.32B Benchmark Subject
BHVN
Biohaven Ltd.
D 44/100 — — -35.0% -1.69% $2.33B /bhvn-vs-pbh →
RCUS
Arcus Biosciences Inc.
E 19/100 — — -35.0% -1.87% $2.32B /rcus-vs-pbh →
PHVS
Pharvaris N.V.
C- 59/100 — — — 0.00% $2.34B /phvs-vs-pbh →
HCM
HUTCHMED (China) Limited
E 34/100 5.2x — -2.5% +0.91% $2.29B /hcm-vs-pbh →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2026-03-31 • CIK 0001295947

In its most recent audited fiscal period (FY2025, filed 2026-03-31), Prestige Consumer Healthcare Inc. (PBH) reported GAAP revenue of $1.09B (-4.3% vs. FY2024 revenue of $1.14B , and -3.3% cumulative change since FY2023) , GAAP net income of $190.3M, operating cash flow of $257.6M, and free cash flow of $246.4M (+1.3% YoY). On the balance sheet, PBH closed FY2025 with $3.49B in total assets against $0 in total debt (Altman Z-Score: 2.21, Piotroski F-Score: 6/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2026-03-31 $1.09B $190.3M $257.6M $246.4M $3.49B —
FY2024 (FY) 2025-03-31 $1.14B $214.6M $251.5M $243.3M $3.33B $1.00B
FY2023 (FY) 2024-03-31 $1.13B $209.3M $248.9M $248.9M — —

3. PBH Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is PBH stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Prestige Consumer Healthcare Inc. (NYSE: PBH) is rated C (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 62/100 at a spot price of $49.73 (+1.37% 1D, market cap $2.32B). Pillar breakdown: Fundamental Cash Engine 14/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 11/20, and SEC Balance-Sheet Forensics 17/20. Across 1016 tracked Health Care issuers, PBH ranks #149 in composite RQD confidence.

How does PBH compare to BHVN and RCUS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), PBH carries a Roarable C (62/100 RQD), trailing P/E of 12.1x, gross margin of 54.7%, and ROIC of 13.8%. By comparison, BHVN (Biohaven Ltd.) holds a D grade (44/100 RQD, P/E N/A, ROIC -35.0%, cap $2.33B) and RCUS (Arcus Biosciences Inc.) posts a E grade (19/100 RQD, P/E N/A, ROIC -35.0%, cap $2.32B). Among the 5-stock peer group, HCM leads on earnings multiple (5.2x) while PBH leads on capital efficiency (13.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for PBH?

Per PBH's SEC EDGAR XBRL 10-K filing (FY2025, filed 2026-03-31, CIK 0001295947), Prestige Consumer Healthcare Inc. generated $1.09B in revenue (-4.3% YoY), $190.3M in net income, and $246.4M in free cash flow against $3.49B in total assets and $0 in total debt. Key quantitative strengths: Company leadership has skin in the game with net positive insider conviction.. Primary risk factors monitored: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is PBH trading relative to its 50-day, 200-day, and 52-week technical levels?

PBH last traded at $49.73 (+1.37% on volume of 596,149 shares), positioning the stock +2.71% above its 50-day simple moving average ($48.42) and -7.77% below its 200-day simple moving average ($53.92). Across its 52-week range of $42.62 to $71.07, PBH sits at the 25.0% percentile with a 14-day RSI of 54.0 (NEUTRAL RANGE) and an implied next-earnings move of ±6.0% ($46.75 to $52.71).

Direct Sub-Reports: PBH RQD Cockpit PBH 12M Forecast PBH Earnings & Move PBH Dividends & DRIP PBH Insiders & 13F PBH Whale Options PBH Profit Sankey PBH News & Why
ROARABLE RATING BRIEF • RQD 62/100 (C) ✓ SEC XBRL & RQD VERIFIED

PBH — Prestige Consumer Healthcare Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-03-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Prestige Consumer Healthcare Inc. (PBH) earns a live Roarable RQD composite score of 62/100, corresponding to a C letter grade (Roarable Hold) at a spot price of $49.73 (+1.37% 1D, market capitalization $2.32B).

  • Fundamental Cash Engine (14/20): Anchored by return on invested capital (ROIC) of 13.8%, gross margin of 54.7%, operating margin of 28.4%, and free cash flow yield of 10.67%.
  • Whale 13F & Options Flow (9/20) + Insider Conviction (11/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (11/20) + Forensic Balance Sheet (17/20): Incorporates a 1.00x equity beta, Altman Z-Score of 2.21, Piotroski F-Score of 6/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Prestige Consumer Healthcare Inc. Is a NYSE-listed issuer in the Health Care sector, operating within the Biotechnology: Pharmaceutical Preparations industry. The profile identifies a market capitalization of $2.3B.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2026-03-31), Prestige Consumer Healthcare Inc. (PBH) reported $1.09B in annual revenue (up from $1.14B in FY2024, -4.3% YoY) and $190.3M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.13B revenue, $209.3M net income) through FY2025, PBH scaled operating cash flow to $257.6M and free cash flow to $246.4M, backed by $3.49B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C • RQD 62/100): Company leadership has skin in the game with net positive insider conviction. Free cash flow yield of 10.67% and institutional whale pillar of 9/20. With Fundamental Cash Engine at 14/20 and Institutional Whale Flow at 9/20, sustained execution supports upside toward the upper end of the $42.62 – $71.07 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins. Investors must weigh 12.1x trailing P/E and 7.0x EV/EBITDA against 28.4% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), PBH carries a macro regime beta of 1.00 and gross margin of 54.7%.

  • Key Question #1: Can PBH sustain or expand its 28.4% operating margin and 13.8% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $1.09B and free cash flow of $246.4M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is PBH's 11.3x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

PBH Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Prestige Consumer Healthcare Inc. (PBH) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to PBH Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

PBH Bull vs. Bear Conversation Board — What's Your Call at $49.73?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON PBH 🐻 33% BEARISH CONVICTION
1. Pick Your Side on PBH:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
SI SiliconVal_Bull RQD DEBATE OPENER • Growth & Tech Investor 🐂 BULLISH 🎯 Target: $57.40 (+17.0%)
📌 Pinned Debate

Insider conviction scores 17/20 and the FCF yield of 10.67% signals strong cash generation at a 12.1 trailing P/E.

The street is overcomplicating Prestige Consumer Healthcare Inc. (PBH). Insider conviction scores 17/20 and the FCF yield of 10.67% signals strong cash generation at a 12.1 trailing P/E.. With an RQD score of 62/100 (C) and Forensic Balance Sheet at 11/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $52.98.

RetailWhale_TX 🐂 BULL

@CreditSpread_Watch Shorting a 9/20 institutional whale-flow stock at $49.06 is dangerous when funds are rotating into Health Care.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $41.21 (-16.0%)
Spot @ $49.06

Revenue and net income declined across FY 2024 to FY 2025 while institutional flow scores only 7/20.

I respect the product at Prestige Consumer Healthcare Inc., but the stock at $49.06 is a different story. Revenue and net income declined across FY 2024 to FY 2025 while institutional flow scores only 7/20.. FCF yield is 10.67% and RQD sits at 62/100 (C) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%